Symmetrical bis-quinolinium compounds: New human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line

Journal of Medicinal Chemistry

Volumn 48, Issue 9, 2005, Pages 3354-3363

  Sánchez Martín, Rosario ^a   Campos, Joaquín M ^a   Conejo García, Ana ^a   Cruz López, Olga ^a   Báñez Coronel, Mónica ^b   Rodríguez González, Agustín ^b   Gallo, Miguel A ^a   Lacal, Juan C ^b   Espinosa, Antonio ^a,c  

^a UNIVERSITY OF GRANADA   (Spain)

^b CSIC   (Spain)

^c Facultad de Farmacia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS(4 AMINO 3 METHYLQUINOLINIUM) DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS(4 AMINO 7 CHLOROQUINOLINIUM) DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS(4 ANILINOQUINOLINIUM) DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS(4 DIMETHYLAMINOQUINOLINIUM) DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS[4 (4 CHLORO N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS[4 (N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS[4 (PERHYDROAZEPINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS[7 AMINO 4 (4 CHLORO N METHYLANILINO) 8 METHYLQUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS[7 AMINO 8 METHYL 4 (N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS[7 CHLORO 4 (4 CHLORO N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS[7 CHLORO 4 (DIMETHYLAMINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS[7 CHLORO 4 (N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 3,3' DIYLMETHYLENE)BIS[7 CHLORO 4 (PYRROLIDINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS(4 AMINO 3 METHYLQUINOLINIUM) DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS(4 AMINO 7 CHLOROQUINOLINIUM) DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[4 (4 CHLORO N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[4 (ANILINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[4 (DIMETHYLAMINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[4 (N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[4 (PERHYDROAZEPINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[7 AMINO 4 (4 CHLORO N METHYLANILINO) 8 METHYLQUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[7 AMINO 8 METHYL 4 (N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[7 CHLORO 4 (4 CHLORO N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[7 CHLORO 4 (DIMETHYLAMINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[7 CHLORO 4 (N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' (BIPHENYL 4,4' DIYLMETHYLENE)BIS[7 CHLORO 4 (PYRROLIDINO)QUINOLINIUM] DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS(4 AMINO 7 CHLOROQUINOLINIUM) DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS[4 (4 CHLORO N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS[4 (ANILINO)QUINOLINIUM] DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS[4 (DIMETHYLAMINO)QUINOLINIUM] DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS[4 (N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS[4 (PERHYDROAZEPINO)QUINOLINIUM] DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS[7 AMINO 4 (4 CHLORO N METHYLANILINO) 8 METHYLQUINOLINIUM] DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS[7 AMINO 8 METHYL 4 (N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS[7 CHLORO 4 (4 CHLORO N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS[7 CHLORO 4 (DIMETHYLAMINO)QUINOLINIUM] DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS[7 CHLORO 4 (N METHYLANILINO)QUINOLINIUM] DIBROMIDE; 1,1' [ETHYLENEBIS(BENZENE 1,4 DIYLMETHYLENE)]BIS[7 CHLORO 4 (PYRROLIDINO)QUINOLINIUM] DIBROMIDE; 4 (4 CHLORO N METHYLANILINO)QUINOLINE; 4 (DIMETHYLAMINO)QUINOLINE; 4 AMINO 3 METHYLQUINOLINE; 4 AMINO 7 CHLOROQUINOLINE; 4 AMINOQUINOLINE; 4 ANILINOQUINOLINE; 4 N (METHYLANILINO)QUINOLINE; 7 CHLORO 4 (DIMETHYLAMINO)QUINOLINE; 7 CHLORO 4 N (METHYLANILINO)QUINOLINE; CHOLINE KINASE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HT29; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; IC 50; LIPOPHILICITY; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BIPHENYL COMPOUNDS; CHOLINE KINASE; HT29 CELLS; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLINES; QUINOLINIUM COMPOUNDS;

EID: 18244382322     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049061o     Document Type: Article

References (50)

1. (a) Kent, C. Regulation of phosphatidylcholine biosynthesis. Prog. Lipid Res. 1990, 29, 87-105.
2. (b) Kennedy, E. P. Biosynthesis of complex lipids. Fed. Proc. 1861, 20, 934-940.
3. Abdellatif, M.; MacLellan, W. R.; Schneider, M. D. p21 Ras as a governor of global gene expression. J. Biol. Chem. 1994, 269, 15423-15426; Wiesmüller, L.; Wittinghofer, F. Signal transduction pathways involving Ras. Mini review. Cell Signal 1994, 6, 247-267; Barbacid, M. ras oncogenes: their role in neoplasia. Eur. J. Clin. Invest. 1990, 20, 225-235.
4. Abdellatif, M.; MacLellan, W. R.; Schneider, M. D. p21 Ras as a governor of global gene expression. J. Biol. Chem. 1994, 269, 15423-15426; Wiesmüller, L.; Wittinghofer, F. Signal transduction pathways involving Ras. Mini review. Cell Signal 1994, 6, 247-267; Barbacid, M. ras oncogenes: their role in neoplasia. Eur. J. Clin. Invest. 1990, 20, 225-235.
5. Abdellatif, M.; MacLellan, W. R.; Schneider, M. D. p21 Ras as a governor of global gene expression. J. Biol. Chem. 1994, 269, 15423-15426; Wiesmüller, L.; Wittinghofer, F. Signal transduction pathways involving Ras. Mini review. Cell Signal 1994, 6, 247-267; Barbacid, M. ras oncogenes: their role in neoplasia. Eur. J. Clin. Invest. 1990, 20, 225-235.
6. Kiaris, H.; Spandidos, D. A. Mutations of ras genes in human tumours. Int. J. Oncol. 1985, 413-421.
7. (a) Teegarden, D.; Taparowsky, E. J.; Kent, C. Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras oncogene. J. Biol. Chem. 1990, 265, 6042-6047.
8. (b) Ratnam, S.; Kent, C. Arch. Biochem. Biophys. 1995, 323, 313-322.
9. (c) Ramirez de Molina, A.; Rodríguez-González, A.; Peñalva, V.; Lucas, L.; Lacal, J. C. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells. Biochem. Biophys. Res. Commun. 2001, 285, 873-879.
10. (d) Ramírez de Molina, A.; Peñalva, V.; Lucas, L.; Lacal, J. C. Regulation of choline kinase activity by Ras proteins involves RaI-GDS and PI3K. Oncogene 2002, 21, 937-946.
11. (a) Ruiz-Cabello, J.; Cohen, J. S. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 1992, 5, 226-233.
12. (b) de Certaines, J. D.; Larsen, V. A.; Podo, F.; Carpinelli, G.; Briot, O.; Henriksen, O. In vivo 31P MRS of experimental tumours. NMR Biomed. 1993, 6, 345-365.
13. (c) Smith, T. A. D.; Bush, C.; Jameson, C.; Titley, J. C.; Leach, M. O.; Wilman, D. E. V.; McCready, V. R. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR Biomed. 1993, 6, 318-323.
14. (a) Cuadrado, A.; Carnero, A.; Dolfi, F.; Jiménez, B.; Lacal, J. C. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993, 8, 2959-2968.
15. (b) Jiménez, B.; del Peso, L.; Montaner, S.; Esteve, P.; Lacal, J. C. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-Kinases in growth factors/induced mitogenic stimulation. J. Cell Biochem. 1995, 57, 141-149.
16. (c) Hernández-Alcoceba, R.; Saniger, L.; Campos, J.; Núñez, M. C.; Khaless, F.; Gallo, M. A.; Espinosa, A.; Lacal, J. C. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997, 15, 2289-2301.
17. Hernández-Alcoceba, R.; Fernández, F.; Lacal, J. C. A novel mechanism for anticancer drug discovery: in vivo antitumor activity by inhibition of phosphorylcholine production. Cancer Res. 1999, 59, 3112-3118.
18. Campos, J.; Núñez, M. C.; Rodríguez, V.; Gallo, M. A.; Espinosa, A. QSAR of 1,1′-(1,2-ethylenebisbenzyl)bis(4- substitutedpyridinium) dibromides as choline kinase inhibitors: a different approach for antiproliferative drug design. Bioorg. Med. Chem. Lett. 2000, 10, 767-770.
19. Campos, J.; Núñez, M. C.; Rodríguez, V.; Entrena, A.; Hernández-Alcoceba, R.; Fernández, F.; Lacal, J. C.; Gallo, M. A.; Espinosa, A. LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase. Eur. J. Med. Chem. 2001, 36, 215-225.
20. Campos, J.; Nuñez, M. C.; Conejo-García, A.; Sánchez-Martín, R. M. Hernández-Alcoceba, R.; Rodríguez-González, A.; Lacal, J. C.; Gallo, M. A.; Espinosa, A. QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be? Curr. Med. Chem. 2003, 10, 1095-1112.
21. Ramírez de Molina, A.; Gutiérrez, R.; Ramos, M. A.; Silva, J. M.; Silva, J.; Sánchez, J. J.; Bonilla, F.; Lacal, J. C. Oncogene 2002, 21, 4317-4322.
22. Ramírez de Molina, A.; Rodríguez-González, A.; Gutiérrez, R.; Martínez-Piñero, L.; Sánchez, J. J.; Bonilla, F.; Rosell, R.; Lacal, J. C. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Commun. 2002, 296, 580-583.
23. Conejo-García, A.; Campos, J.; Sánchez, R. M.; Rodríguez-González, A.; Juan C. Lacal, Gallo, M. A.; Espinosa, A. Choline kinase inhibitory effect and antiproliferative activity of new 1,1′,1″-(benzene-1,3,5-triylmethylene)tris{4-[(disubstituted)amino] pyridinium} tribromides. Eur. J. Med. Chem. 2003, 38, 109-116.
24. Conejo-García, A.; Campos, J. M.; Sánchez-Martín, R. M.; Gallo, M. A.; Espinosa, A. Bispyridmium cyclophanes: novel templates for human choline kinase inhibitors. J. Med. Chem. 2003, 46, 3754-3757.
25. Conejo-García, A.; Campos, J. M.; Entrena, A.; Sánchez-Martín, R. M.; Gallo, M. A.; Espinosa, A. Conformational dynamics of a bispyridinium cyclophane. J. Org. Chem. 2003, 68, 8697-8699.
26. Conejo-García, A.; Báñez-Coronel, M.; Sánchez-Martín, R. M.; Rodríguez-González, A.; Ramos, A.; Ramírez de Molina, A.; Espinosa, A.; Gallo, M. A.; Campos, J. M.; Lacal, J. C. Influence of the linker in bispyridinium compounds on the inhibition of human choline kinase. J. Med. Chem. 2004, 47, 5433-5440.
27. Conejo-García, A.; Entrena, A.; Campos, J. M.; Sánchez-Martín, R. M.; Gallo, M. A.; Espinosa, A. Towards a model for the inhibition of choline kinase by a new type of inhibitor. Eur. J. Med. Chem. 2004, 315-319.
28. Hauser, C. R.; Reynolds, G. A. Relative ease of cyclization of 2-, 3- and 4-aminopyridine derivatives. Synthesis of naphthyridines. J. Org. Chem. 1950, 15, 1224-1232.
29. Watanabe, T.; Tanaka, Y.; Sekiya, K.; Akita, Y.; Ohta, A. A convenient synthesis of methylamino- and dimethylamino-substituted aromatic compounds. Synthesis 1980, 39-41.
30. Galanakis, D.; Calder, J.; Ganellin, C. R.; Owen, C. S.; Dunn, P. M. Synthesis and quantitative structure-activity relationships of dequalinium analogues as K+ channel blockers: investigation into the role of the substituent at position 4 of the quinoline ring. J. Med. Chem. 1995, 38, 3536-3546.
31. Backeberg, O. G. Action of phosphoryl chloride on the toluene-p-sulfonyl derivative of β-anilinopropionic acid. J. Chem. Soc. 1933, 618-619.
32. Vippagunta, S. R.; Dorn, A.; Matile, H.; Bhattacharjee, A. K.; Karle, J. M.; Ellis, W. Y.; Ridley, R. G.; Vennerstrom, J. L. Structural specificity of chloroquine-hematin binding related to inhibition of hematin polymerization and parasite growth. J. Med. Chem. 1989, 42, 4630-4639.
33. Gupton, J. T.; Wysong, E.; Norman, B.; Hertel, G.; Idoux, J. P. The reaction of activated aryl and heteroaryl dihalides with HMPA. A regioselectivity study. Synth. Commun. 1985, 15, 43-52.
34. Hauser, C. R.; Weiss, M. J. Substitutions at the α- or γ-positions in pyridyl ring systems by basic reagents. J. Org. Chem. 1949, 14, 310-321.
35. Kayirere, M.-G.; Mahamoud, A.; Chevalier, J.; Soyfer, J.-C.; Crémieux, A.; Barbe, J. Synthesis and antibacterial activity of new 4-alkoxy, 4-aminoalkyl and 4-alkylthioquinoline derivatives. Eur. J. Med. Chem. 1998, 33, 55-64.
36. Wenner, W. Bis(bromomethyl)compounds. J. Org. Chem. 1952, 17, 523-528.
37. Szendey, G. L.; Munnes, S. Konstitution und eigenschaften des biphenylen-(4,4′)-bis-[methylatropiniumbromids], einer biquartären atropinverbindung. (Constitution and properties of biphenylene-(4,4′)- bis[methylatropinium] bromide, a bisquaternary atropine compound). Chem. Ber. 1881, 94, 38-42.
38. Staab, H. A.; Haenel, M. Synthesen won [2.2](4,4′)biphenylophan, [2.2](2,7)phenanthrenophan und [2](4,4′)biphenylo[2](2,7)- phenanthrenophan. Chem. Ber. 1973, 106, 2190-2202.
39. Cram, D. J.; Steinberg, H. Macro rings. I. Preparation and spectra of the paracyclophanes. J. Am. Chem. Soc. 1951, 73, 5691-5704.
40. Campos Rosa, J.; Galanakis, D.; Ganellin, C. R.; Dunn, P. M. Synthesis, molecular modeling, and K+ channel-blocking activity of dequalinium analogues having semirigid linkers. J. Med. Chem. 1996, 39, 4247-4254.
41. Schnall, S.; Macdonald, J. S. In Manual of Oncologic Therapeutics; Macdonald, J. S., Haller, D. G., Mayer, R. J., Eds.; J. B. Lippincott Co.: Philadelphia, 1995; pp. 170-184.
42. Viswanadhan, V. N.; Ghose, A. K.; Revankar, G. R.; Robins, P. K. Atomic physicochemical parameters for three-dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.
43. PALLAS FRAME MODULE, a prediction tool of physicochemical parameters, is supplied by CompuDrug Chemistry, Ltd, PO Box 23196, Rochester, NY 14692.
44. Kubinyi, H. QSAR: Hansch Analysis and Related Approaches. In Methods and Principles in Medicinal Chemistry; Mannhold, R., Krogsgaard-Larsen, P., Timmerman, H., Eds.; VCH: Weinheim. 1993: Vol. 1, pp 40-41.
45. Blaney, J. M.; Hansch, C. Quantitative Drug Design (Ramsden, C. A., Ed.). In Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study & Terapeutic Application of Chemical Compounds; Hansch, C., Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press: Oxford, 1990; Vol. 4, pp 459-496.
46. Hansch, C. Blaney, J. M. Chemische Struktur und biologische Aktivität von Wirkstoffen. Methoden der Quantitativen Struckutr-Wirkung- Analyse; Seydel J. K., Schaper, K.-J., Eds.; Verlag Chemie: Weinheim, 1979; pp 185-208.
47. Hansch, C.; Leo, A. Substituent constants for correlation analysis in chemistry and biology; John Wiley & Sons: New York, 1979.
48. Campos, J. M.; Núñez, M. C.; Sánchez, R. S.; Gómez-Vidal, J. A.; Rodríguez-González, A.; Báñez, M.; Gallo, M. A.; Lacal, J. C.; Espinosa, A. Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds. Bioorg. Med. Chem. 2002, 10, 2215-2231.
49. Lucas, L.; Hernández-Alcoceba, R.; Rodríguez, P.; Lacal, J. C. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Oncogene 2001, 20, 1110-1117.
50. Ramírez de Molina, A.; Peñalva, V.; Lucas, L.; Lacal, J. C. Regulation of choline kinase activity by Ras proteins involves RaI-GDS and PI3K. Oncogene 2002, 21, 937-946.